Cost-effectiveness of Tenofovir / Emtricitabine / Efavirenz versus Zidovudine / Lamivudine / Efavirenz as fist-line regimens for the treatment of HIV-infected patients in low-income settings

Details

Ressource 1Download: BIB_85A17E2C290D.P001.pdf (294.81 [Ko])
State: Public
Version: After imprimatur
Serval ID
serval:BIB_85A17E2C290D
Type
A Master's thesis.
Collection
Publications
Institution
Title
Cost-effectiveness of Tenofovir / Emtricitabine / Efavirenz versus Zidovudine / Lamivudine / Efavirenz as fist-line regimens for the treatment of HIV-infected patients in low-income settings
Author(s)
Azzabi-Zouraq Ismail
Director(s)
Chevrou-Séverac Hélène
Institution details
Université de Lausanne, Faculté des hautes études commerciales
Address
Lausanne
Publication state
Accepted
Issued date
2007
Genre
Mémoire / Institute of Health Economics and Management ; no 118
Language
french
Number of pages
38 f.
Notes
DESS en économie et management de la santé - Master in Health Economics and Management (MHEM) Mention de responsabiblité : / Ismail Azzabi-Zouraq ; supervisors: Hélène Chevrou-Séverac & Philipp Storz SAPHIRID:67900
Abstract
The Highly Active Antiretroviral Therapy (HAART) is the combination of at least three antiretroviral compounds. The combination purpose is to reduce the likelihood of drug resistance. However in the long-term the resistance to the first-line combination occurs and leads to treatment failure. Thus, a second-line and even a third-line regimen are recommended in the long run. [...] [P. 5]
The two treatment alternatives under comparison: Tenofovir (300 mg) CO-formulated with Emtricitabine (200 mg) and Efavirenz (600 mg) currently known under the brand name Atripla (R) was introduced in July 2006 in the United States market. The excellent safety profile and ease of use make this combination a perfect first-line regimen in low-income settings. Therefore, this treatment option was recommended in WHO 2006 reviewed guidelines. Unfortunately, Tenofovir and Emtricitabine compounds are still costly and not yet widely available. For a matter of simplification this regimen is referred in this report as "the recent" therapy.
Initially, we had in mind to consider the most frequently used first-line regimen in low-income countries (Stavudine / Larnivudme / Nevirapine) as a comparator for this economic evaluation. Unfortunately, according to the literature review results (see Annex 3); there was no data available comparing head to head the effectiveness of this regimen with the recent one. Instead, we selected a less frequently but commonly used first-line regimen in low-income countries as a comparator: Zidovudine, Lamivudine, Efavirenz. This combination has extensive experience in durability, safety and toxicity and seems to be an optimal choice for a first-line regimen according to the clinical trial group 384 team. Furthermore, Zidovudine, one of the compounds of this combination is now recommended as one of the preferred NNRTI [Non Nucleoside Reverse Transcriptase Inhibitors] options to be considered by countries instead of Stavudine (the most used NNRTI in limited-income countries). As this combination has been included in the WHO guidelines as a first-line therapy since 2003 when WHO launched the "3 by 5" scaling-up initiative, this combination of drugs is referred in this report as the "old" therapy.
Objectives: The primary objective of this economic evaluation is to compare the two first-line HAARTs introduced above, in a low-income setting context. Both of these combinations are recommended by the 2006 WHO guidelines as potential first-line regimens. The secondary objective is to provide a simplified and comprehensible cost-effectiveness modeling tool in order to help policy makers, in resource-limited settings, make decisions about which first-line HAART to fund using the scarce resources available. [P. 6-7]
Keywords
Anti-HIV Agents , Antiretroviral Therapy, Highly Active , Cost-Benefit Analysis , tenofovir , emtricitabine , efavirenz , Zidovudine , Lamivudine , Acquired Immunodeficiency Syndrome , HIV Infections
Create date
05/07/2010 16:52
Last modification date
20/08/2019 15:45
Usage data